PULMATRIX, INC. Increase Decrease In Operating Lease Liability
PULMATRIX, INC. (PULM) reported Increase Decrease In Operating Lease Liability of -$333.00 thousand for the 12-month period ending 2024-12-31, per its S-4/A filed 2026-09-17.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-09-17
- PULMATRIX, INC. increase decrease in operating lease liability for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- PULMATRIX, INC. increase decrease in operating lease liability for the quarter ending 2024-09-30 was -$24.00K.
- PULMATRIX, INC. increase decrease in operating lease liability for the quarter ending 2024-06-30 was -$165.00K.
- PULMATRIX, INC. increase decrease in operating lease liability for the quarter ending 2024-03-31 was -$144.00K.
- PULMATRIX, INC. increase decrease in operating lease liability for fiscal 2023 was -$3.04M.
- PULMATRIX, INC. increase decrease in operating lease liability for fiscal 2022 was -$1.43M.
- PULMATRIX, INC. increase decrease in operating lease liability for fiscal 2021 was -$1.13M.
- PULMATRIX, INC. increase decrease in operating lease liability for fiscal 2020 was -$619.00K.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: S-4/A 12 month − 10-Q 9 month · filed 2026-09-17 | -$24.00K derived: sum of 2 quarters · filed 2026-09-17 | -$189.00K derived: sum of 3 quarters · filed 2026-09-17 | -$333.00K S-4/A · filed 2026-09-17 |
| 2024-09-30 | -$24.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-16 | -$189.00K derived: sum of 2 quarters · filed 2025-10-16 | -$333.00K 10-Q · filed 2025-10-16 | $9.00K derived: sum of 4 quarters · filed 2025-10-16 |
| 2024-06-30 | -$165.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$309.00K 10-Q · filed 2025-08-06 | $33.00K derived: sum of 3 quarters · filed 2025-08-06 | -$2.51M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | -$144.00K 10-Q · filed 2025-05-15 | $198.00K derived: sum of 2 quarters · filed 2025-05-15 | -$2.34M derived: sum of 3 quarters · filed 2025-05-15 | -$2.76M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $342.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-21 | -$2.20M derived: sum of 2 quarters · filed 2025-03-21 | -$2.62M derived: sum of 3 quarters · filed 2025-03-21 | -$3.04M 10-K · filed 2025-03-21 |
| 2023-09-30 | -$2.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | -$2.96M derived: sum of 2 quarters · filed 2024-11-08 | -$3.38M 10-Q · filed 2024-11-08 | -$3.81M derived: sum of 4 quarters · filed 2024-11-08 |
| 2023-06-30 | -$421.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$843.00K 10-Q · filed 2024-08-13 | -$1.27M derived: sum of 3 quarters · filed 2024-08-13 | -$1.69M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | -$422.00K 10-Q · filed 2024-05-10 | -$846.00K derived: sum of 2 quarters · filed 2024-05-10 | -$1.27M derived: sum of 3 quarters · filed 2024-05-10 | -$1.56M derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | -$424.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | -$845.00K derived: sum of 2 quarters · filed 2024-03-28 | -$1.14M derived: sum of 3 quarters · filed 2024-03-28 | -$1.43M 10-K · filed 2024-03-28 |
| 2022-09-30 | -$421.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$715.00K derived: sum of 2 quarters · filed 2023-11-09 | -$1.01M 10-Q · filed 2023-11-09 | -$1.29M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$294.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$586.00K 10-Q · filed 2023-08-10 | -$867.00K derived: sum of 3 quarters · filed 2023-08-10 | -$1.15M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$292.00K 10-Q · filed 2023-05-12 | -$573.00K derived: sum of 2 quarters · filed 2023-05-12 | -$859.00K derived: sum of 3 quarters · filed 2023-05-12 | -$1.14M derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | -$281.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | -$567.00K derived: sum of 2 quarters · filed 2023-03-30 | -$848.00K derived: sum of 3 quarters · filed 2023-03-30 | -$1.13M 10-K · filed 2023-03-30 |
| 2021-09-30 | -$286.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$567.00K derived: sum of 2 quarters · filed 2022-11-10 | -$845.00K 10-Q · filed 2022-11-10 | -$997.00K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$281.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | -$559.00K 10-Q · filed 2022-08-10 | -$711.00K derived: sum of 3 quarters · filed 2022-08-10 | -$861.00K derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | -$278.00K 10-Q · filed 2022-05-12 | -$430.00K derived: sum of 2 quarters · filed 2022-05-12 | -$580.00K derived: sum of 3 quarters · filed 2022-05-12 | -$733.00K derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | -$152.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | -$302.00K derived: sum of 2 quarters · filed 2022-03-29 | -$455.00K derived: sum of 3 quarters · filed 2022-03-29 | -$619.00K 10-K · filed 2022-03-29 |
| 2020-09-30 | -$150.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$303.00K derived: sum of 2 quarters · filed 2021-11-10 | -$467.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | -$153.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | -$317.00K 10-Q · filed 2021-08-10 | ||
| 2020-03-31 | -$164.00K 10-Q · filed 2021-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |